GSK has agreed to acquire Nuvalent for $11 billion, adding two experimental lung cancer drugs to its pipeline. The deal, the British drugmaker's third acquisition this year, brings in therapies targeting ALK and ROS1 mutations that are currently under FDA review.
The two drugs, designed for non-small cell lung cancer, represent a bet on targeted therapies in a competitive field. Nuvalent's pipeline includes clinical-stage candidates that have shown promise in early trials, though detailed efficacy data remains limited in the announced deal.
Regulatory filings are already underway, with both therapies under FDA review. The acquisition positions GSK to potentially bring the drugs to market pending agency decisions, though specific PDUFA dates were not disclosed.
Shares of Nuvalent rose on the news, reflecting investor enthusiasm for the premium GSK offered. For GSK, the deal bolsters its oncology franchise in a market projected to grow significantly as targeted lung cancer treatments gain traction.
The counter argument: the $11 billion price tag raises questions about valuation, given the drugs are still awaiting approval and face stiff competition from established ALK and ROS1 inhibitors already on the market.